The role of allogeneic stem cell transplant in advanced acute promyelocytic leukemia patients who received standard first and second-line therapy is still unknown. We report the outcome of 31 acute promyelocytic leukemia patients (median age 39) who underwent allogeneic transplant in second-remission (15patients) or beyond (16patients. Sixteen patients were RT-PCR positive and 15 negative for PML/RARA pre-transplant. The 4-year overall-survival was 62 % and 31% for patients transplanted in second-remission and beyond, respectively (p=0.05) and 64% and 27% for patients with RT-PCR-negative and positive pre-transplant, respectively (p=0.03). The 4-year cumulative-incidence of relapse was 32% and 44% for patients transplanted in second-remission and beyond, respectively (p=0.37) and 30% and 47% for patients transplanted with negative and positive RT-PCR, respectively (p=0.30). Transplant-related mortality was 19.6%. In conclusion, allogeneic transplant is effective in advanced acute promyelocytic leukemia in the all-trans-retinoic acid and arsenic trioxide era and should be considered once relapse is diagnosed.

Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era / Ramadan, S. M.; A., Di Veroli; A., Camboni; M., Breccia; Iori, A. P.; Aversa, Franco; L., Cupelli; C., Papayannidis; A., Bacigalupo; W., Arcese; F., Lo Coco. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 97:11(2012), pp. 1731-1735. [10.3324/haematol.2013.101279]

Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era

AVERSA, Franco;
2012-01-01

Abstract

The role of allogeneic stem cell transplant in advanced acute promyelocytic leukemia patients who received standard first and second-line therapy is still unknown. We report the outcome of 31 acute promyelocytic leukemia patients (median age 39) who underwent allogeneic transplant in second-remission (15patients) or beyond (16patients. Sixteen patients were RT-PCR positive and 15 negative for PML/RARA pre-transplant. The 4-year overall-survival was 62 % and 31% for patients transplanted in second-remission and beyond, respectively (p=0.05) and 64% and 27% for patients with RT-PCR-negative and positive pre-transplant, respectively (p=0.03). The 4-year cumulative-incidence of relapse was 32% and 44% for patients transplanted in second-remission and beyond, respectively (p=0.37) and 30% and 47% for patients transplanted with negative and positive RT-PCR, respectively (p=0.30). Transplant-related mortality was 19.6%. In conclusion, allogeneic transplant is effective in advanced acute promyelocytic leukemia in the all-trans-retinoic acid and arsenic trioxide era and should be considered once relapse is diagnosed.
2012
Allogeneic stem cell transplantation for advanced acute promyelocytic leukemia in the ATRA and ATO era / Ramadan, S. M.; A., Di Veroli; A., Camboni; M., Breccia; Iori, A. P.; Aversa, Franco; L., Cupelli; C., Papayannidis; A., Bacigalupo; W., Arcese; F., Lo Coco. - In: HAEMATOLOGICA. - ISSN 0390-6078. - 97:11(2012), pp. 1731-1735. [10.3324/haematol.2013.101279]
File in questo prodotto:
File Dimensione Formato  
Ramadan , haematol 2012.PDF

non disponibili

Tipologia: Documento in Post-print
Licenza: NON PUBBLICO - Accesso privato/ristretto
Dimensione 324.72 kB
Formato Adobe PDF
324.72 kB Adobe PDF   Visualizza/Apri   Richiedi una copia

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11381/2438497
Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 20
  • ???jsp.display-item.citation.isi??? 4
social impact